10月1日,诺和诺德公布STEP UP试验一项亚组事后分析结果:在接受司美格鲁肽(商品名Wegovy,2.4 mg国内商品名诺和盈)治疗72周后,基线肝脏脂肪含量超过5%的肥胖症成人中,88.5%的受试者肝脏脂肪降至5%以下,恢复至正常水平。该数据于正在意大利米兰举行的2026年欧洲糖尿病研究协会(EASD)年会上公布。 需指出的是,该结果为探索性事后分析:肝脏脂肪经磁共振成像质子密度脂肪分数(...
Source Link10月1日,诺和诺德公布STEP UP试验一项亚组事后分析结果:在接受司美格鲁肽(商品名Wegovy,2.4 mg国内商品名诺和盈)治疗72周后,基线肝脏脂肪含量超过5%的肥胖症成人中,88.5%的受试者肝脏脂肪降至5%以下,恢复至正常水平。该数据于正在意大利米兰举行的2026年欧洲糖尿病研究协会(EASD)年会上公布。 需指出的是,该结果为探索性事后分析:肝脏脂肪经磁共振成像质子密度脂肪分数(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.